Streetbeat News

Price Targets

BRZE

JMP Securities analyst Patrick Walravens reiterated an Outperform rating on Braze (NASDAQ:BRZE) and maintained a $46 price target.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 3:16 pm

EXPI

EXp World Holdings shares are trading higher after DA Davidson reiterated a Buy rating on the stock and raised its price target from $14.5 to $20.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 3:11 pm

CAH

In the last 3 months, 7 analysts have provided 12-month price targets for Cardinal Health (NYSE:CAH), with an average price target of $85.86, up 4.92% from the previous average of $81.83.

Portfolio Pulse from Benzinga Insights

June 09, 2023 | 3:03 pm

CRSP

In the last 3 months, 17 analysts have offered 12-month price targets for CRISPR Therapeutics (NASDAQ:CRSP), with an average price target of $66.29, up 12.99% from the previous average of $58.67. The ratings include 5 bullish, 4 somewhat bullish, 7 indifferent, and 1 somewhat bearish.

Portfolio Pulse from Benzinga Insights

June 09, 2023 | 3:02 pm

BNTX

HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on BioNTech (NASDAQ:BNTX) and maintained a $181 price target.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 2:57 pm

CRSP

EF Hutton analyst Tony Butler reiterates a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) and maintains a $75 price target.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 2:53 pm

KROS

HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Keros Therapeutics (NASDAQ:KROS) and maintained a $100 price target.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 2:51 pm

DOCU

JP Morgan analyst Mark Murphy maintains an Underweight rating on DocuSign (NASDAQ: DOCU) and raises the price target from $48 to $50.

Portfolio Pulse from richadhand@benzinga.com

June 09, 2023 | 2:51 pm

CAH

JP Morgan analyst Lisa Gill maintains a Neutral rating on Cardinal Health (NYSE:CAH) and raises the price target from $90 to $93.

Portfolio Pulse from richadhand@benzinga.com

June 09, 2023 | 2:50 pm

BRZE

JP Morgan analyst Pinjalim Bora maintains an Overweight rating on Braze (NASDAQ:BRZE) and raises the price target from $36 to $40.

Portfolio Pulse from richadhand@benzinga.com

June 09, 2023 | 2:48 pm